macular degeneration

(redirected from Age-related macular degeneration)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms.
Related to Age-related macular degeneration: glaucoma, diabetic retinopathy

macular degeneration,

eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. The most serious visual impairment occurs when abnormal blood vessels form and leak serous fluid or bleed into the tissue of the macula, ultimately producing scar tissue. Peripheral (side) vision is unaffected. Onset may be acute with hemorrhage but usually is gradually progressive. Although some vision is retained, the ability to read, recognize faces, and drive a motor vehicle is greatly reduced. The condition is painless.

Macular degeneration is a major cause of vision impairment among elderly people. Although its underlying cause is unknown, it sometimes appears to run in families. Serious macular degeneraton, if diagnosed early, may have its progress stemmed by laser or photodynamic (cold laser and drug) treatment that closes leaking vessels. Antiangiogenic drugs, which inhibit the formation of new blood vessels, can be injected into the eye to stop degeneration and in some cases even improve vision. Sudden change in vision in someone over age 50 thus requires immediate medical attention.

Bibliography

See H. Grunwald, Twilight: Losing Sight, Gaining Insight (1999).

References in periodicals archive ?
An international classification and grading system for age related maculopathy and age-related macular degeneration.
Visual acuity has now been shown to be increased in at least one study of lutein, zeaxanthin, and omega-3 fatty acids, along with the expected increases in protective pigment density, in those with early age-related macular degeneration.
Chapter 3 provides an overview of the leading age-related macular degeneration deals since 2009.
National Eye Institute Statement on Study Associating Moderate Wine Consumption With Decreased Risk of Age-Related Macular Degeneration.
The NEI reports that age-related macular degeneration is the leading cause of blindness in individuals over 65, although some researchers consider the disease to be the main cause of blindness in people as young as 50.
The Company's primary goal is to develop and commercialize the first breakthrough antiangiogenic drug to reduce vision loss caused by neovascular age-related macular degeneration.
This report provides insights into Age-Related Macular Degeneration epidemiology, Age-Related Macular Degeneration diagnosed patients, and Age-Related Macular Degeneration treatment rate for top seven pharmaceutical markets.
When combined with a third carotenoid called meso-zeaxanthin, the three have been found to provide even greater benefits for people with early age-related macular degeneration.
Eleven million people in the United States have some form of age-related macular degeneration.
The second edition of Age-Related Macular Degeneration presents a collection of essays by over sixty international medical contributors on the subjects of intravenous fluorescein angiography, indocyanine green angiography, and optical coherence tomography, among many other issues related to macular degeneration.
Age-related macular degeneration (ARMD) is the most common cause of permanent visual loss in the elderly.
Biopharmaceutical company Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Bayer HealthCare on Monday jointly announced the initiation of a Phase three clinical study of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China .